Author: admin

“Gaucher Disease Treatment Market”

(Albany, USA) DelveInsight’s “Gaucher’s Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Gaucher’s Disease Market Size and Share in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

As per DelveInsight’s assessment, the Gaucher Disease market size in the 7MM is anticipated to increase in the coming years owing to the rising prevalent population of Gaucher Disease patients in the 7MM countries. The launch of the upcoming therapies will also fuel market growth.

To Know in detail about the Gaucher Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gaucher Disease Market Forecast

Some of the key facts of the Gaucher Disease Market Report:

• The Gaucher Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• According to Zimran et al. (2022), estimations for GD type undefined or overall prevalence ranged from 0.11 to 139.0/100,000 people, with North America having the greatest prevalence rates (GD1: 0.26-0.63; GD2 and GD3: 0.02- 0.08)
• According to Hughes & Sidransky (2023), type 1 GD (GD1) is the most common form in the US, Europe, and affects Ashkenazi Jews more frequently than other populations. All ethnic types experience Type 2 GD (GD2). According to a gene frequency research, there were about 20,000 cases of GD in the United States in the middle of the 1990s. The standardised birth incidence of GD in the general population was estimated by a later survey to be between 0.4 and 5.8 per 100,000, with a prevalence of 0.7 to 1.8 per 100,000
• An genetic metabolic condition is known as Gaucher Disease (GD). NORD estimates that there are around 6,000 people in the US who have GD. It is inherited from parents to offspring and is brought on by a GBA gene issue
• Key Gaucher Disease Companies: Sanofi, Avro Bio, Freeline Therapeutics, CANbridge, Sanofi, Pfizer, ISU Abxis Co., Ltd., Shire, Actelion, Amicus Therapeutics, Quintiles, Inc., and others
• Key Gaucher Disease Therapies: Venglustat, AVR-RD-02, FLT201, CAN103, venglustat (GZ402671), Elelyso, ISU302, VPRIV, Miglustat, afegostat tartrate, velaglucerase, and others
• The Gaucher Disease epidemiology based on gender analyzed that females born with GD does not have any family history whereas male child born with GD have family history
• The Gaucher Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gaucher Disease pipeline products will significantly revolutionize the Gaucher Disease market dynamics.
• In May 2025, Spur Therapeutics announced results of a Phase 1, Open-label, Safety, Tolerability, and Efficacy Study of FLT201 in Adult Patients With Gaucher Disease Type 1 (GALILEO-1)
• In March 2025, Genzyme, a Sanofi Company announced results of a 4-part, Open-label, Multicenter, Multinational Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic, and Exploratory Efficacy of Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension
• In March 2025, Prevail Therapeutics announced results of an Open-label, Dose-Finding, Phase 1/2 Study to Evaluate the Safety and Tolerability of a Single Intravenous Dose of LY3884961 in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
• In February 2025, Lingyi Biotech Co., Ltd. Announced results of a Multicenter, Open, Single-arm, Single-dose, Dose-escalation, and Expanded Phase I/II Study Evaluating the Safety, Tolerability, and Efficacy of LY-M001 Injection in Adult Patients With Type I Gaucher Disease
• In January 2025, Sanofi announced results of a Phase 3, Multicenter, Multinational, Randomized, Double-blind, Double-dummy, Active-comparator Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3 (GD3) Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ERT)

Gaucher Disease Overview

Gaucher Disease is a rare, inherited lysosomal storage disorder caused by a deficiency of the enzyme glucocerebrosidase. Gaucher Disease leads to the accumulation of fatty substances in organs such as the spleen, liver, and bone marrow, affecting their normal function. Gaucher Disease symptoms vary widely but commonly include enlarged liver and spleen, bone pain, fatigue, and easy bruising. Gaucher Disease is classified into three main types: Gaucher Disease Type 1 (non-neuronopathic), Gaucher Disease Type 2 (acute neuronopathic), and Gaucher Disease Type 3 (chronic neuronopathic).

Gaucher Disease diagnosis is confirmed through enzyme assays and genetic testing. Gaucher Disease treatment typically includes enzyme replacement therapy (ERT) and substrate reduction therapy (SRT), aimed at managing symptoms and improving quality of life. Gaucher Disease management requires regular monitoring of organ function and bone density. Gaucher Disease research continues to explore gene therapy and novel treatments for better outcomes.

Gaucher Disease awareness is crucial for early detection and timely intervention. Gaucher Disease affects individuals of all ethnicities but is most prevalent among Ashkenazi Jewish populations. Gaucher Disease support groups and patient communities play a vital role in education and emotional support. Gaucher Disease prognosis depends on the type and severity, with many patients leading productive lives with proper care.

Explore the intricate details of the Gaucher’s Disease Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Gaucher’s Disease Market Forecast. Click here to stay ahead in healthcare innovation @ Gaucher’s Disease Market Size Report

Gaucher Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Gaucher Disease Epidemiology Segmentation:

The Gaucher Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Gaucher Disease
• Prevalent Cases of Gaucher Disease by severity
• Gender-specific Prevalence of Gaucher Disease
• Diagnosed Cases of Episodic and Chronic Gaucher Disease

Download the report to understand which factors are driving Gaucher Disease epidemiology trends @ Gaucher Disease Prevalence

Gaucher Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gaucher Disease market or expected to get launched during the study period. The analysis covers Gaucher Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gaucher Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Gaucher Disease Therapies and Key Companies

• Venglustat: Sanofi
• AVR-RD-02: Avro Bio
• FLT201: Freeline Therapeutics
• CAN103: CANbridge
• venglustat (GZ402671): Sanofi
• Elelyso: Pfizer
• ISU302: ISU Abxis Co., Ltd.
• VPRIV: Shire
• Miglustat: Actelion
• afegostat tartrate: Amicus Therapeutics

• velaglucerase: Quintiles, Inc.

Discover more about therapies set to grab major Gaucher Disease market share @ Gaucher’s Disease Companies and Medication

Gaucher Disease Market Strengths

• Increasing awareness of Gaucher disease
• Advances in the understanding of Gaucher disease pathogenesis
• Pipeline consists of late and early stage candidates.

Gaucher Disease Market Opportunities

• Uptake of potential emerging therapies with better clinical profile expected to be medium-fast due to the present unmet needs.
• Several organizations are actively working to provide information and increase awareness of such disorders.

Scope of the Gaucher Disease Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Gaucher Disease Companies: Sanofi (EPA: SAN), Avro Bio (NASDAQ: AVRO), Freeline Therapeutics (NASDAQ: FRLN), CANbridge Pharmaceuticals (HKEX: 1228), Pfizer (NYSE: PFE), ISU Abxis Co., Ltd. (KOSDAQ: 086890), Shire (formerly NASDAQ: SHPG, acquired by Takeda), Actelion (SWX: ATLN, acquired by Johnson & Johnson), Amicus Therapeutics (NASDAQ: FOLD), and Quintiles, Inc.
• Key Gaucher Disease Therapies: Venglustat, AVR-RD-02, FLT201, CAN103, venglustat (GZ402671), Elelyso, ISU302, VPRIV, Miglustat, afegostat tartrate, velaglucerase, and others
• Gaucher Disease Therapeutic Assessment: Gaucher Disease current marketed and Gaucher Disease emerging therapies
• Gaucher Disease Market Dynamics: Gaucher Disease market drivers and Gaucher Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Gaucher Disease Unmet Needs, KOL’s views, Analyst’s views, Gaucher Disease Market Access and Reimbursement

To know more about Gaucher Disease companies working in the treatment market, visit @ Gaucher’s Disease Clinical Trials and FDA Approvals

Table of Contents

1. Gaucher Disease Market Report Introduction

2. Executive Summary for Gaucher Disease

3. SWOT analysis of Gaucher Disease

4. Gaucher Disease Patient Share (%) Overview at a Glance

5. Gaucher Disease Market Overview at a Glance

6. Gaucher Disease Disease Background and Overview

7. Gaucher Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Gaucher Disease

9. Gaucher Disease Current Treatment and Medical Practices

10. Gaucher Disease Unmet Needs

11. Gaucher Disease Emerging Therapies

12. Gaucher Disease Market Outlook

13. Country-Wise Gaucher Disease Market Analysis (2019–2032)

14. Gaucher Disease Market Access and Reimbursement of Therapies

15. Gaucher Disease Market Drivers

16. Gaucher Disease Market Barriers

17. Gaucher Disease Appendix

18. Gaucher Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/ats-conference-coverage

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gaucher Disease Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, NICE Approvals, Therapies and Companies by DelveInsight

“Infusion Pumps Market”

(Albany, USA) DelveInsight’s Infusion Pumps Market Insights report provides the current and forecast market analysis, individual leading infusion pumps companies’ market shares, challenges, infusion pumps market drivers, barriers, trends, and key market infusion pumps companies in the market.

The infusion pumps market is experiencing significant growth due to the increasing demand for advanced healthcare solutions, particularly in the management of chronic diseases and critical care. Technological advancements, such as the integration of smart pumps with connectivity features and automation, are driving market expansion.

Recent Developments in the Infusion Pumps Market

• In April 2025, ICU Medical Inc. received 510(k) clearance from the FDA for the Plum Solo precision IV pump, a single-channel device designed to complement the dual-channel Plum Duo.
• In March 2025, the FDA released an early warning regarding a ‘potentially high-risk’ concern with specific Baxter Sigma Spectrum and Spectrum IQ infusion pumps.
• In November 2024, Boston Scientific initiated an agreement to acquire Intera Oncology, a privately owned company that provides the FDA-approved Intera 3000 hepatic artery infusion pump and floxuridine.
• In November 2024, Avanos Medical, Inc. stated that the Centers for Medicare and Medicaid Services (CMS) had released its final rule for the 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS) and Medicare Ambulatory Surgical Center (ASC) Payment System.

To read more about the latest highlights related to the infusion pumps market, get a snapshot of the key highlights entailed in the infusion pumps medical devices pipeline product analysis @ Global Infusion Pumps Market Report

Infusion Pumps Overview

Infusion pumps are medical devices used to deliver fluids, such as nutrients and medications, into a patient’s body in controlled amounts. They are commonly used in hospitals, nursing homes, and sometimes in home settings, especially for patients requiring long-term treatments. These devices offer precise control over the rate and duration of fluid administration, making them particularly useful for delivering critical medications like insulin, chemotherapy drugs, antibiotics, and pain relievers. Infusion pumps can be programmed to deliver fluids continuously, intermittently, or in patient-controlled doses, depending on the therapeutic need.

There are several types of infusion pumps, including volumetric pumps, syringe pumps, and elastomeric pumps, each suited to different medical applications. Advanced models feature safety mechanisms like alarms for occlusion, air bubbles, or empty reservoirs, helping prevent dosing errors. Recent technological developments have led to smart pumps that integrate with electronic health records and use drug libraries to enhance safety and efficiency. As healthcare increasingly embraces digital and remote monitoring tools, infusion pumps continue to evolve, contributing significantly to better patient outcomes and streamlined clinical workflows.

Infusion Pumps Regional Market Insights

The infusion pumps market is experiencing robust growth across various regions, driven by advancements in healthcare infrastructure and the increasing prevalence of chronic diseases that require infusion therapy, such as diabetes, cancer, and cardiovascular diseases. North America holds a significant share in the global market, primarily due to the presence of key market players, well-established healthcare infrastructure, and rising healthcare expenditure.

The United States, in particular, remains a leading market owing to high adoption rates of advanced infusion pump technologies, including smart pumps that enhance precision in drug delivery. The growing demand for home healthcare services is further propelling the adoption of infusion pumps in this region, with a focus on improving patient safety and reducing hospital stays.

In Europe, the infusion pumps market is also seeing growth, driven by an aging population and increasing investments in healthcare technology. The European market benefits from government support for healthcare advancements and a strong network of hospitals and healthcare providers. The trend of outpatient care and home healthcare is growing in this region, and countries like Germany, France, and the UK are seeing increasing demand for infusion pumps in home settings.

Additionally, regulatory support and reimbursement policies are further boosting market growth. In the Asia-Pacific region, rapid improvements in healthcare infrastructure and rising disposable incomes in countries like China and India are creating a burgeoning market for infusion pumps. The expanding number of healthcare facilities and growing awareness regarding advanced medical technologies are expected to drive the demand for infusion pumps in the region in the coming years.

To know more about why North America is leading the market growth in the infusion pumps market, get a snapshot of the Dynamic Infusion Pumps Market

Key Players in the Infusion Pumps Market

​The global infusion pumps market is led by several key players, each contributing significantly to the industry’s growth and innovation. Becton Dickinson (BD) stands out as a dominant force, particularly after its strategic acquisition of CareFusion. BD’s Alaris® product line offers a modular system that includes various modules such as the Alaris™ PC Unit, Pump Module, Syringe Module, PCA Module, Auto-ID Module, and EtCO2, providing comprehensive solutions for healthcare settings.

Other significant players operating in the infusion pumps market include B. Braun Melsungen AG, Baxter International Inc., Boston Scientific Corporation, Medtronic plc., Fresenius Kabi, CareFusion Corporation, Smiths Medical, Koninklijke Philips NV, Micrel Medical Devices SA, Terumo Corporation, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., F. Hoffmann-La Roche Ltd., Johnson & Johnson, CME Medical UK Ltd., and others.

Which MedTech key players in the infusion pumps market are set to emerge as the trendsetter explore @ Infusion Pumps and Accessories Market

Infusion Pumps Market Key Factor Analysis

Infusion Pumps Market Drivers

The infusion pumps market is experiencing significant growth driven by the increasing prevalence of chronic diseases such as cancer, diabetes, and other long-term conditions. As these diseases require ongoing treatment and management, the demand for infusion pumps—vital for delivering medications, nutrients, and fluids to patients—has risen substantially. Furthermore, the rising occurrence of Hospital-Acquired Infections (HAIs) has highlighted the need for precise and reliable infusion pumps to reduce the risk of complications during medical treatments.

The growing number of surgical procedures in which infusion pumps are crucial for administering anesthetics and fluids during surgeries further contributes to the expansion of the market. This combination of factors is accelerating the need for advanced, high-precision devices that ensure the safety and effectiveness of treatments.

In addition to these factors, the increasing demand for remote patient monitoring is driving innovation in the infusion pumps sector. Remote monitoring technologies allow healthcare providers to track patient conditions and adjust treatment protocols in real time, making infusion pumps an essential part of telehealth solutions. The rise in such technologies, coupled with increasing patient mobility, has pushed for more user-friendly, portable, and connected infusion pumps that enhance the patient experience and improve clinical outcomes.

Additionally, the rapid approval and launch of new infusion pump models across the globe have played a key role in propelling market growth. Manufacturers are continually investing in research and development to introduce smarter, more efficient, and safer pumps, further fueling the market’s expansion and meeting the needs of an ever-growing patient base.

Infusion Pumps Market Restraints and Challenges

The infusion pumps market faces several restraints and challenges, primarily driven by regulatory hurdles and the complexity of manufacturing. Stringent regulations and the need for approval from health authorities like the FDA or EMA create delays in product launches and introduce additional costs for manufacturers. These regulatory processes ensure safety and efficacy, but they can be cumbersome for companies trying to bring new or innovative infusion pumps to market. Moreover, the complexity involved in designing pumps that are compatible with different drug formulations, delivery methods, and patient conditions increases the risk of technical failures, which can undermine patient safety and result in financial losses for manufacturers.

Another key challenge in the infusion pumps market is the rising concern about safety and device recalls. High-profile incidents involving device malfunctions, errors in medication delivery, or user misuse can harm a company’s reputation and erode trust in its products. Furthermore, the increased competition from lower-cost alternatives and the need for continuous innovation to improve pump features and functionalities create pricing pressures. As healthcare systems seek cost-effective solutions, manufacturers are forced to balance between high-tech innovation and affordability, which can limit their ability to meet market demands while maintaining profit margins. Additionally, there is an increasing demand for training healthcare professionals to use these devices effectively, which adds another layer of complexity and cost to the market.

Infusion Pumps Market Opportunities

The integration of infusion pumps with Electronic Health Records (EHRs) presents significant market opportunities in the healthcare sector. This integration enables real-time tracking and monitoring of infusion therapies, enhancing patient safety and improving clinical workflows. By connecting infusion pumps to EHRs, healthcare providers can ensure that infusion data is automatically recorded, reducing the chances of manual errors and improving accuracy in dosing and treatment administration. Furthermore, the integration allows for better decision-making, as clinicians can access a comprehensive view of a patient’s treatment history, including medication infusions, in one centralized system.

This streamlined approach not only enhances operational efficiency but also supports better patient outcomes by enabling more personalized and data-driven treatment plans. As hospitals and healthcare systems continue to adopt digital health solutions, the demand for infusion pumps that offer seamless EHR integration is expected to rise, creating a promising market opportunity for manufacturers and technology providers.

Get a sneak peek at the infusion pumps market dynamics @ Infusion Pumps Medical Devices Pipeline Product Analysis

Infusion Pumps Market Report Metrics

• Coverage: Global
• Study Period: 2022–2032
• Infusion Pumps Market CAGR: ~10%
• Infusion Pumps Market Size in 2032: USD 23.85 Billion
• Key Infusion Pumps Companies: B. Braun Melsungen AG, Baxter International Inc. (NYSE: BAX), Boston Scientific Corporation (NYSE: BSX), Medtronic plc (NYSE: MDT), Fresenius Kabi (ETR: FRE), CareFusion Corporation (NYSE: BDX), Smiths Medical (LSE: SMIN), Koninklijke Philips NV (AMS: PHIA), Micrel Medical Devices SA, Terumo Corporation (TYO: 4543), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760), F. Hoffmann-La Roche Ltd. (SWX: RO), Johnson & Johnson (NYSE: JNJ), CME Medical UK Ltd., and BD (NYSE: BDX), among others.

Infusion Pumps Market Assessment

• Infusion Pumps Market Segmentation By Type: Volumetric Pumps, Syringe Pumps, Enteral Pumps, Insulin Pumps, Elastomeric Pumps, Implantable Pumps, and Patient-Controlled Analgesia Pumps
• Infusion Pumps Market Segmentation By Application: Diabetes, Oncology, Pain Management, Gastroenterology, and Others
• Infusion Pumps Market Segmentation By End User: Hospitals & Clinics, Ambulatory Care Settings, Home Care Settings, and Others
• Infusion Pumps Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Interested in knowing the infusion pumps market by 2032? Click to get a snapshot of the Infusion Pumps Market Trends

Table of Contents

1. Infusion Pumps Market Report Introduction

2. Infusion Pumps Market Executive Summary

3. Competitive Landscape

4. Regulatory Analysis

5. Infusion Pumps Market Key Factors Analysis

6. Infusion Pumps Market Porter’s Five Forces Analysis

7. Infusion Pumps Market Layout

8. Infusion Pumps Market Company and Product Profiles

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/ats-conference-coverage

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Infusion Pumps Market Projected to Grow at a Robust CAGR of ~10% by 2032, Driven by Technological Advancements and Rising Healthcare Demand | DelveInsight

“Glioblastoma Drugs Market”

(Albany, USA) DelveInsight’s “Glioblastoma Market Insights, Epidemiology and Market Forecast– 2034” report delivers an in-depth understanding of the Glioblastoma, historical and forecasted epidemiology as well as the Glioblastoma market trends in the United States, the EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

The Glioblastoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Glioblastoma market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Glioblastoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Glioblastoma market.

The pipeline review for the glioblastoma treatment market highlights a dynamic landscape of ongoing clinical trials and emerging therapies aimed at addressing this aggressive brain cancer. Several biopharmaceutical companies are actively developing novel approaches, including targeted therapies, immunotherapies, and gene-based treatments. The glioblastoma treatment pipeline also features advancements in personalized medicine and biomarker-driven strategies. This evolving pipeline holds promise for improving patient outcomes and expanding therapeutic options in the coming years.

Discover which therapies are expected to grab the Glioblastoma Market Share @ Glioblastoma Market Outlook

Key Takeaways from the Glioblastoma Market Report

• The increase in Glioblastoma Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Glioblastoma Market is anticipated to witness growth at a considerable CAGR.

• The leading Glioblastoma Companies working in the market include Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai, Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, and TME Pharma, and others.

• Promising Glioblastoma Pipeline Therapies in the various stages of development include ITI-1000 (pp65 DC Vaccine), VBI-1901, Selinexor (KPT-330), Trans Sodium Crocetinate, Ofranergene obadenovec (VB-111), Temodar/Temodal, Avastin, Azeliragon, PLX3397, Temozolomide, VXM01, Avelumab, and others.
• In May 2025, CNS Pharmaceuticals Inc. announced a study that is an open-label, multicenter, randomized, parallel, 2-arm, efficacy and safety study. Patients with GBM after failure of standard first line therapy will be randomized in a 2:1 ratio to receive berubicin or lomustine for the evaluation of OS. Additional endpoints will include response and progression outcomes evaluated by a blinded central reviewer for each patient according to RANO criteria.
• In May 2025, In8bio Inc . Conducted a Phase 1b/2 study is being conducted to determine if the experimental cell therapy is safe, tolerable and can delay the return of cancer in patients with a newly diagnosed or recurrent glioblastoma multiforme (GBM) in combination with standard chemotherapy treatment temozolomide (TMZ). If there is a 25% or greater improvement in survival in this study then the therapy should be studied further.
• In April 2025, Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has approved an Investigational Device Exemption (IDE) application to initiate a pilot study for the treatment of patients with recurrent glioblastoma (GBM) using the Alpha DaRT technology.
• In December 2024, Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today provided a regulatory update on paxalisib for the treatment of glioblastoma (GBM) following its Type C clinical meeting with the United States Food and Drug Administration (FDA).
• On October 15, 2024, the FDA granted Fast Track designation to LP-184, a small-molecule alkylating agent developed by Lantern Pharma for the treatment of glioblastoma (GBM). LP-184 induces tumor cell death through DNA damage and is currently in a Phase 1a trial assessing its safety and tolerability in patients with various solid tumors, including GBM. The Fast Track status aims to accelerate the development and review of LP-184, particularly given the limited treatment options for aggressive brain cancers like GBM.
• April 2024:- Boston Scientific Corporation- FRONTIER: A Feasibility Study to Evaluate the Safety of the TheRaSphere GliOblastoma (GBM) Device iN PaTIEnts With Recurrent GBM. Glioblastoma (GBM) is a highly aggressive brain cancer with a grave prognosis, resulting in <7% of patients surviving to five years post-diagnosis. External beam radiotherapy (EBRT) is currently a mainstay treatment for GBM; however, the dose delivered is limited by side effects. The targeted radiotherapy of the TheraSphere GBM Y-90 Glass Microsphere System (TheraSphere GBM) has promising potential to provide GBM patients with reduced side effects compared to external beam radiotherapy as well as a more effective treatment for this catastrophic disease.
• April 2024:- TJ Biopharma Co., Ltd. – A Phase 2, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT). A Phase 2, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients with Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT).

Stay ahead in oncology R&D with our latest pipeline review glioblastoma treatment market overview, covering immunotherapies and targeted agents, visit @ Glioblastoma Treatment Market Landscape

Glioblastoma Overview

Glioblastoma (GBM) is an aggressive and the most common primary malignant brain tumor in adults. Classified as a grade IV astrocytoma by the World Health Organization, it originates from astrocytes, the supportive glial cells in the brain. GBM is characterized by rapid growth, extensive infiltration into surrounding brain tissue, and significant heterogeneity at the cellular and molecular levels.

Patients often present with neurological symptoms such as headaches, seizures, cognitive decline, or focal deficits, depending on the tumor’s location. Diagnosis typically involves magnetic resonance imaging (MRI) and confirmation via biopsy or surgical resection, which also serves as an initial treatment step.

Standard treatment includes maximal safe surgical resection, followed by concurrent radiotherapy and temozolomide chemotherapy. Despite aggressive multimodal therapy, GBM remains highly resistant to treatment, with a median survival of 15–18 months. Recurrence is almost inevitable, and treatment options for recurrent disease are limited.

Molecular profiling of GBM, including markers like MGMT promoter methylation and IDH mutation status, guides prognosis and treatment decisions. Emerging therapies, such as tumor-treating fields (TTFs), immunotherapy, and targeted molecular inhibitors, are under investigation. While these advances offer hope, GBM remains a formidable challenge, highlighting the urgent need for innovative therapies.

Glioblastoma Epidemiology Insights

The epidemiology section of Glioblastoma offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

Download the report to understand which factors are driving Glioblastoma Epidemiology trends @ Glioblastoma Epidemiological Insights

Glioblastoma Drugs Market

The Glioblastoma Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Glioblastoma signaling in Glioblastoma are likely to uncover new therapeutic targets and further expand treatment options for patients.

Glioblastoma Treatment Market Landscape

The Glioblastoma treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Glioblastoma has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

Glioblastoma Market Outlook

The report’s outlook on the Glioblastoma market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Glioblastoma therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Glioblastoma drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Glioblastoma market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

Glioblastoma Drugs Uptake

The drug chapter of the Glioblastoma report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Glioblastoma.

A comprehensive pipeline review glioblastoma treatment market analysis reveals promising investigational drugs and upcoming clinical trial milestones.

Learn more about the FDA-approved drugs for Glioblastoma @ Drugs for Glioblastoma Treatment

Major Glioblastoma Companies

Several Glioblastoma Companies working in the market include Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai, Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, and TME Pharma, and others.

Scope of the Glioblastoma Market Research Report

• Coverage- 7MM

• Glioblastoma Companies- Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai, Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, and TME Pharma, and others.

• Glioblastoma Pipeline Therapies- ITI-1000 (pp65 DC Vaccine), VBI-1901, Selinexor (KPT-330), Trans Sodium Crocetinate, Ofranergene obadenovec (VB-111), Temodar/Temodal, Avastin, Azeliragon, PLX3397, Temozolomide, VXM01, Avelumab, and others.
• Glioblastoma Market Dynamics: Glioblastoma Market Drivers and Barriers
• Glioblastoma Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Glioblastoma Drugs in development @ Glioblastoma Clinical Trials and FDA Approvals

Table of Content

1. Key Insights

2. Report Introduction

3. Glioblastoma Multiforme Market Overview at a Glance

4. Epidemiology and Market Forecast Methodology

5. Executive Summary of Glioblastoma Multiforme (GBM)

6. Key Events

7. Glioblastoma SWOT Analysis

8. Disease Background and Overview: Glioblastoma Multiforme

9. Glioblastoma Treatment

10. Guidelines and Recommendations from Different Organizations

11. Glioblastoma Epidemiology and Patient Population

12. Glioblastoma Patient Journey

13. Key Endpoints in Glioblastoma Multiforme

14. Glioblastoma Marketed Products

15. Emerging Glioblastoma Drugs

16. Glioblastoma Market: Seven Major Market Analysis

17. Glioblastoma KOL Views

18. Glioblastoma Unmet Needs

19. Glioblastoma Market Access and Reimbursement

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/ats-conference-coverage

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Glioblastoma Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, NICE Approvals, Therapies and Companies by DelveInsight

“Fabry Disease Treatment Market”

(Albany, USA) DelveInsight’s “Fabry Disease Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Fabry Disease, historical and forecasted epidemiology as well as the Fabry Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Fabry Disease market report provides current treatment practices, emerging drugs, the market share of tmarkets. The Report also covers current Fabry Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Fabry Disease market.

Request for a Free Sample Report @ Fabry Disease Market Forecast

Some facts of the Fabry Disease Market Report are:

• According to DelveInsight, Fabry Disease market size is expected to grow at a decent CAGR by 2034.
• As per DelveInsight analysis, the Fabry disease market size in the 7MM was approximately USD ~1700 million in 2024.
• As per the analysis conducted by DelveInsight, in 2022 the total diagnosed prevalent cases of Fabry disease was 15,290 in the 7MM and these cases are further projected to increase during the study period (2020-2034).
• Leading Fabry Disease companies working in the market are Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, GREENOVATION BIOTECH GMBH, Shire, Takeda, Amicus Therapeutics, Protalix, uniQure, Codexis, MP6 Therapeutics, CellGenTech, and others.
• Key Fabry Disease Therapies expected to launch in the market are PRX-102 (Pegunigalsidase Alfa), Venglustat, ST-920, FLT190, 4D-310, Lucerastat, Moss-aGal, and others.
• In February 2025, Amicus Therapeutics presented oral sessions and posters highlighting its migalastat development programs at the 21st Annual WORLD Symposium.
• In January 2025 presentation, Idorsia Pharmaceuticals shared that they expect the Phase III Open-label Extension (OLE) study results in Q2 2025 and plan to discuss the regulatory pathway with the US FDA thereafter.
• In January 2025, Sanofi announced that the regulatory submission for venglustat for Fabry disease is anticipated in 2026.
• In December 2024, CHIESI Farmaceutici and Protalix BioTherapeutics announced that the EMA had validated the variation submission for pegunigalsidase alfa to label a less frequent dosing regimen at a dose of 2 mg/kg body weight administered every 4 weeks in adult patients with Fabry disease.
• In September 2024, UniQure Biopharma mentioned that with the support of the designation for its Phase I/IIa clinical trial, the company is eager to rapidly generate clinical proof-of-concept data and provide initial results in 2025.
• On March 2024, Sanofi announced results of a Phase 4 study which evaluates the safety and tolerability of Fabrazyme at current approved dose with increases in the infusion rate and reduced infusion volume. This study aims to generate data to provide the guidance on how infusion rate can be safely increased and minimize the burden of the life-long treatment with Fabrazyme.
• On April 2024, 4D Molecular Therapeutics announced results of an Open-Label, Phase 1/2a Trial of Gene Therapy 4D-310 in Adults With Fabry Disease and Cardiac Involvement

Fabry Disease Overview

Fabry Disease is a rare, inherited lysosomal storage disorder caused by a deficiency of the enzyme alpha-galactosidase A. Fabry Disease leads to the accumulation of globotriaosylceramide (Gb3) in various tissues, including the kidneys, heart, and nervous system. Fabry Disease symptoms can include chronic pain, angiokeratomas, heat intolerance, corneal opacities, and gastrointestinal issues. Fabry Disease diagnosis typically involves enzyme assay testing and genetic analysis to confirm mutations in the GLA gene. Fabry Disease primarily affects males, but female carriers can also exhibit Fabry Disease-related complications due to X-linked inheritance.

Fabry Disease progression can result in life-threatening complications such as Fabry Disease-induced renal failure, Fabry Disease-related cardiomyopathy, and Fabry Disease-associated stroke. Fabry Disease treatment includes enzyme replacement therapy (ERT) and pharmacological chaperones that help reduce Gb3 accumulation. Fabry Disease management also involves symptomatic care and regular monitoring of Fabry Disease biomarkers. Fabry Disease awareness is increasing due to advances in Fabry Disease research and clinical trials focused on gene therapy and novel treatment approaches. Early Fabry Disease screening can significantly improve patient outcomes. Fabry Disease specialists, including nephrologists, cardiologists, and geneticists, play a crucial role in personalized care. Comprehensive Fabry Disease education is essential for early detection, timely intervention, and better quality of life.

Learn more about Fabry Disease treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Fabry Disease Drugs Market

Fabry Disease Market

The Fabry Disease market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Fabry Disease market trends by analyzing the impact of current Fabry Disease therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Fabry Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Fabry Disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

The Fabry Disease market is driven by several key factors. Increasing awareness about rare genetic disorders and advancements in diagnostic technologies have led to earlier and more accurate diagnosis of Fabry Disease, facilitating timely treatment. The development of innovative therapies, such as enzyme replacement therapy (ERT) and pharmacological chaperones, has expanded the treatment landscape and improved patient outcomes, further propelling market growth. Additionally, rising healthcare expenditure, favorable reimbursement policies in developed countries, and growing investment in research and development by pharmaceutical companies contribute significantly to the market’s expansion. Strategic collaborations and regulatory support for orphan drugs also play a pivotal role in encouraging innovation and accessibility.

However, the Fabry Disease market faces notable barriers. The high cost of treatment, particularly ERT, poses a substantial financial burden on patients and healthcare systems, limiting access in low- and middle-income regions. Limited awareness and diagnostic capabilities in some parts of the world contribute to underdiagnosis or misdiagnosis, delaying treatment initiation. Moreover, the small patient population characteristic of rare diseases often results in limited clinical data and challenges in conducting large-scale clinical trials. These factors, along with stringent regulatory requirements and long development timelines, can hinder the timely introduction of new therapies into the market.

According to DelveInsight, the Fabry Disease market in 7MM is expected to witness a major change in the study period 2020-2034.

Fabry Disease Epidemiology

The Fabry Disease epidemiology section provides insights into the historical and current Fabry Disease patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Fabry Disease market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Fabry Disease Epidemiology @ Fabry Disease Prevalence

As per DelveInsight’s assessments, in the 7MM Fabry Disease is more prevalent in males than in females but there are some differences at the regional level

Fabry Disease Drugs Uptake

This section focuses on the uptake rate of the potential Fabry Disease drugs recently launched in the Fabry Disease market or expected to be launched in 2020-2034. The analysis covers the Fabry Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Fabry Disease Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Fabry Disease market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Fabry Disease Pipeline Development Activities

The Fabry Disease report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Fabry Disease key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Fabry Disease pipeline development activities @ Fabry Disease Clinical Trials and FDA Approvals

Fabry Disease Pipeline Therapies and Key Companies

• PRX-102 (Pegunigalsidase Alfa): Protalix Biotherapeutics
• Venglustat: Sanofi Genzyme
• ST-920: Sangamo Therapeutics
• FLT190: Freeline Therapeutics
• 4D-310: 4D Molecular Therapeutics
• Lucerastat: Idorsia Pharmaceuticals
• Moss-aGal: GREENOVATION BIOTECH GMBH

Fabry Disease Therapeutics Assessment

Major key companies are working proactively in the Fabry Disease Therapeutics market to develop novel therapies which will drive the Fabry Disease treatment markets in the upcoming years are Protalix Biotherapeutics (NYSE: PLX), Sanofi Genzyme (EPA: SAN), Sangamo Therapeutics (NASDAQ: SGMO), Freeline Therapeutics (NASDAQ: FRLN), 4D Molecular Therapeutics (NASDAQ: FDMT), Idorsia Pharmaceuticals (SWX: IDIA), GREENOVATION BIOTECH GMBH, Shire (formerly NASDAQ: SHPG), Takeda (TSE: 4502), Amicus Therapeutics (NASDAQ: FOLD), uniQure (NASDAQ: QURE), Codexis (NASDAQ: CDXS), MP6 Therapeutics, CellGenTech, Protalix (NYSE: PLX) and others.

Learn more about the emerging Fabry Disease therapies & key companies @ Fabry Disease Treatment Market

Fabry Disease Report Key Insights

1. Fabry Disease Patient Population

2. Fabry Disease Market Size and Trends

3. Key Cross Competition in the Fabry Disease Market

4. Fabry Disease Market Dynamics (Key Drivers and Barriers)

5. Fabry Disease Market Opportunities

6. Fabry Disease Therapeutic Approaches

7. Fabry Disease Pipeline Analysis

8. Fabry Disease Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Fabry Disease Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Fabry Disease Competitive Intelligence Analysis

4. Fabry Disease Market Overview at a Glance

5. Fabry Disease Disease Background and Overview

6. Fabry Disease Patient Journey

7. Fabry Disease Epidemiology and Patient Population

8. Fabry Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Fabry Disease Unmet Needs

10. Key Endpoints of Fabry Disease Treatment

11. Fabry Disease Marketed Products

12. Fabry Disease Emerging Therapies

13. Fabry Disease Seven Major Market Analysis

14. Attribute Analysis

15. Fabry Disease Market Outlook (7 major markets)

16. Fabry Disease Access and Reimbursement Overview

17. KOL Views on the Fabry Disease Market

18. Fabry Disease Market Drivers

19. Fabry Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/ats-conference-coverage

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Fabry Disease Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, NICE Approvals, Therapies and Companies by DelveInsight

“Deep Vein Thrombosis Treatment Market”

(Albany, USA) DelveInsight’s “Deep Vein Thrombosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Deep Vein Thrombosis, historical and forecasted epidemiology as well as the Deep Vein Thrombosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Deep Vein Thrombosis, offering comprehensive insights into the Deep Vein Thrombosis revenue trends, prevalence, and treatment landscape. The report delves into key Deep Vein Thrombosis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Deep Vein Thrombosis therapies. Additionally, we cover the landscape of Deep Vein Thrombosis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Deep Vein Thrombosis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Deep Vein Thrombosis space.

To Know in detail about the Deep Vein Thrombosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Deep Vein Thrombosis Market Forecast

Some of the key facts of the Deep Vein Thrombosis Market Report:

• The Deep Vein Thrombosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• Key Deep Vein Thrombosis Companies: Bayer, LEO Pharma, Agen Biomedical, Bristol-Myers Squibb, Sanofi, Ottawa Hospital Research Institute, Daiichi Sankyo, MinaPharm Pharmaceuticals, GlaxoSmithKline, Pfizer, Anthos Therapeutics, Inc., and others
• Key Deep Vein Thrombosis Therapies: Rivaroxaban, innohep®, ThromboView, Apixaban, SanOrg34006, Tinzaparin, edoxaban tosylate, r-Hirudin, Fondaparinux sodium, PD 0348292, Dalteparin, and others
• The Deep Vein Thrombosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Deep Vein Thrombosis pipeline products will significantly revolutionize the Deep Vein Thrombosis market dynamics.
• The Centers for Disease Control and Prevention (CDC) (2023) reports that while the exact number of individuals affected by DVT or PE is uncertain, it is estimated that up to 900,000 people may be impacted annually in the United States.
• According to Waheed et al. (2023), over 200,000 individuals in the United States develop venous thrombosis each year, with 50,000 cases complicated by pulmonary embolism. The annual incidence of DVT is 80 cases per 100,000 people, with a prevalence of lower limb DVT at 1 case per 1,000 population.
• Waheed et al. (2023) noted that deep vein thrombosis is uncommon in children, and the risk significantly rises with age, with most cases occurring in individuals over 40.
• The CDC (2023) states that about 33% of individuals with DVT or PE will experience a recurrence within 10 years.
• In April 2025, Bayer announced results of a Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of BAY 3018250 in Patients With Symptomatic Proximal Deep Vein Thrombosis

Deep Vein Thrombosis Overview

Deep Vein Thrombosis (DVT) is a serious vascular condition characterized by the formation of blood clots in deep veins, commonly in the legs. Deep Vein Thrombosis symptoms may include leg swelling, pain, redness, and warmth, although some individuals experience no symptoms at all. Deep Vein Thrombosis causes include prolonged immobility, surgery, trauma, cancer, pregnancy, and inherited clotting disorders. Deep Vein Thrombosis diagnosis is typically confirmed through ultrasound imaging, D-dimer tests, or venography.

Deep Vein Thrombosis treatment focuses on preventing clot growth and reducing the risk of pulmonary embolism. Common Deep Vein Thrombosis treatments include anticoagulant medications such as heparin and warfarin, compression stockings, and in severe cases, thrombolytic therapy. Deep Vein Thrombosis prevention strategies involve regular movement during long periods of inactivity, hydration, and use of prophylactic anticoagulants when medically necessary.

Deep Vein Thrombosis complications can be life-threatening if the clot dislodges and travels to the lungs, causing a pulmonary embolism. Deep Vein Thrombosis awareness and early intervention are crucial in preventing long-term consequences like post-thrombotic syndrome. Deep Vein Thrombosis prognosis improves significantly with prompt medical attention and adherence to treatment protocols.

Get a Free sample for the Deep Vein Thrombosis Drugs Market Size & Analysis Report: Deep Vein Thrombosis Pipeline Analysis

Deep Vein Thrombosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Deep Vein Thrombosis Epidemiology Segmentation:

The Deep Vein Thrombosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalent Cases of DVT in the 7MM
• Diagnosed Prevalent Cases of DVT in the 7MM
• Age-specific Cases of DVT in the 7MM
• Total Treated Cases of DVT in the 7MM

Download the report to understand which factors are driving Deep Vein Thrombosis epidemiology trends @ Deep Vein Thrombosis Epidemiology Forecast

Deep Vein Thrombosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Deep Vein Thrombosis market or expected to get launched during the study period. The analysis covers Deep Vein Thrombosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Deep Vein Thrombosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Deep Vein Thrombosis Therapies and Key Companies

• Rivaroxaban: Bayer
• innohep®: LEO Pharma
• ThromboView: Agen Biomedical
• Apixaban: Bristol-Myers Squibb
• SanOrg34006: Sanofi
• Tinzaparin: Ottawa Hospital Research Institute
• edoxaban tosylate: Daiichi Sankyo
• r-Hirudin: MinaPharm Pharmaceuticals
• Fondaparinux sodium: GlaxoSmithKline
• PD 0348292: Pfizer
• Dalteparin: Anthos Therapeutics, Inc.

Discover more about therapies set to grab major Deep Vein Thrombosis market share @ Deep Vein Thrombosis Treatment Landscape

Deep Vein Thrombosis Market Strengths

• The use of off-label branded and generic prescription medications targeted at individual symptoms of DVT.
• Several academic institutions and pharmaceutical companies are currently conducting clinical trials for the treatment of various symptoms of DVT.

Deep Vein Thrombosis Market Opportunities

• New therapeutic options are needed to address the unmet need for effective and curative therapies for DVT. This has created an opportunity for key players to develop novel therapies targeted towards this indication.

Scope of the Deep Vein Thrombosis Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Deep Vein Thrombosis Companies: Bayer, LEO Pharma, Agen Biomedical, Bristol-Myers Squibb, Sanofi, Ottawa Hospital Research Institute, Daiichi Sankyo, MinaPharm Pharmaceuticals, GlaxoSmithKline, Pfizer, Anthos Therapeutics, Inc., and others
• Key Deep Vein Thrombosis Therapies: Rivaroxaban, innohep®, ThromboView, Apixaban, SanOrg34006, Tinzaparin, edoxaban tosylate, r-Hirudin, Fondaparinux sodium, PD 0348292, Dalteparin, and others
• Deep Vein Thrombosis Therapeutic Assessment: Deep Vein Thrombosis current marketed and Deep Vein Thrombosis emerging therapies
• Deep Vein Thrombosis Market Dynamics: Deep Vein Thrombosis market drivers and Deep Vein Thrombosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Deep Vein Thrombosis Unmet Needs, KOL’s views, Analyst’s views, Deep Vein Thrombosis Market Access and Reimbursement

To know more about Deep Vein Thrombosis companies working in the treatment market, visit @ Deep Vein Thrombosis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Deep Vein Thrombosis Market Report Introduction

2. Executive Summary for Deep Vein Thrombosis

3. SWOT analysis of Deep Vein Thrombosis

4. Deep Vein Thrombosis Patient Share (%) Overview at a Glance

5. Deep Vein Thrombosis Market Overview at a Glance

6. Deep Vein Thrombosis Disease Background and Overview

7. Deep Vein Thrombosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Deep Vein Thrombosis

9. Deep Vein Thrombosis Current Treatment and Medical Practices

10. Deep Vein Thrombosis Unmet Needs

11. Deep Vein Thrombosis Emerging Therapies

12. Deep Vein Thrombosis Market Outlook

13. Country-Wise Deep Vein Thrombosis Market Analysis (2019–2032)

14. Deep Vein Thrombosis Market Access and Reimbursement of Therapies

15. Deep Vein Thrombosis Market Drivers

16. Deep Vein Thrombosis Market Barriers

17. Deep Vein Thrombosis Appendix

18. Deep Vein Thrombosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/ats-conference-coverage

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Deep Vein Thrombosis Treatment Market 2032: Clinical Trials, Treatment Medication, EMA, PDMA, FDA Approvals, Epidemiology, NICE Approvals, Therapies, Companies by DelveInsight

“Cholangiocarcinoma Market”

(Albany, USA) DelveInsight’s “Cholangiocarcinoma Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Cholangiocarcinoma, historical and forecasted epidemiology as well as the Cholangiocarcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Cholangiocarcinoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Cholangiocarcinoma market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Cholangiocarcinoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Cholangiocarcinoma market.

Request for a Free Sample Report @ Cholangiocarcinoma Market Forecast

Some facts of the Cholangiocarcinoma Market Report are:

• According to DelveInsight, Cholangiocarcinoma market size is expected to grow at a decent CAGR by 2034.
• In 2021, the total Cholangiocarcinoma market size was USD 786.1 million which is expected to rise during the study period (2020-2034).
• Leading Cholangiocarcinoma companies working in the market are AstraZeneca, Decalth Systems, Power Life Sciences, Genfit, Servier Affaires Médicales, Basilea Pharmaceutica, Taiho Oncology, Eisai Pharmaceuticals, TransThera Sciences, Incyte Corporation, Roche, Agios Pharmaceuticals, Servier Pharmaceuticals, and Others.
• Key Cholangiocarcinoma Therapies expected to launch in the market are PEMAZYRE (pemigatinib), TIBSOVO (ivosidenib), LYTGOBI (futibatinib), and others.
• In April 2025, Servier (Servier Affaires Médicales) announced an Open-Label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
• In February 2025, Eisai Inc. announced results of a Multicenter, Open-Label, Phase 2 Trial of E7090 in Subjects With Unresectable Advanced or Metastatic Cholangiocarcinoma With FGFR 2 Gene Fusion
• In January 2025, Servier announced results of a Phase 2, Open-label, Multicenter Study of Orally Administered Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
• In December 2024, Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company revolutionizing drug discovery through advanced computational and experimental technologies, and Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. focused on improving treatment outcomes for patients with limited therapeutic options, announced today an exclusive global licensing agreement for lirafugratinib (RLY-4008). Lirafugratinib is a selective oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), being developed for patients with FGFR2-driven cholangiocarcinoma (CCA) and other FGFR2-altered solid tumors. The partnership follows Relay’s recent positive FDA interaction and previously reported promising data in cholangiocarcinoma and other solid tumors.
• In September 2024, Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to certepetide for the treatment of cholangiocarcinoma.
• On March 2024, Genfit announced an open-label, multicenter Phase 1b/2a study to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of GNS561 in combination with trametinib in Advanced KRAS Mutated Cholangiocarcinoma after failure of standard-of-care first line therapy.
• On Feb 2024, TransThera Sciences (Nanjing), Inc announced a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma
• On March 2023, Power Life Sciences Inc announced a Clinical Study Experiences of Cholangiocarcinoma Patients to Identify Trial Attributes Affecting Completion Rates for Specific Demographic Groups.

Learn more about Cholangiocarcinoma treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Cholangiocarcinoma Treatment Market

Cholangiocarcinoma Overview

Cholangiocarcinoma, also known as bile duct cancer, is a rare but aggressive form of cancer originating in the bile ducts, which transport bile from the liver to the small intestine. This cancer is classified into three types based on its location: intrahepatic (within the liver), perihilar (at the liver’s hilum), and distal (further down the bile duct). The majority of cholangiocarcinomas are adenocarcinomas, which arise from the mucus glands in the bile duct.

Risk factors for cholangiocarcinoma include primary sclerosing cholangitis, chronic liver disease, bile duct cysts, liver flukes, and certain genetic conditions. Symptoms often appear late and may include jaundice, abdominal pain, weight loss, and itching, making early detection challenging.

Diagnosis typically involves imaging studies such as MRI, CT scans, and cholangiography, along with biopsy and blood tests. Treatment options vary depending on the cancer’s stage and location but may include surgery, radiation therapy, chemotherapy, and targeted therapies. Liver transplantation is an option for some patients with early-stage disease.

Despite advances in treatment, the prognosis for cholangiocarcinoma remains poor, emphasizing the need for ongoing research and improved therapeutic strategies. Early diagnosis and multidisciplinary care are crucial for enhancing patient outcomes.

Request for Sample Report @ Cholangiocarcinoma Drugs Market

Cholangiocarcinoma Market

The Cholangiocarcinoma market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Cholangiocarcinoma market trends by analyzing the impact of current Cholangiocarcinoma therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Cholangiocarcinoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Cholangiocarcinoma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Cholangiocarcinoma market in 7MM is expected to witness a major change in the study period 2020-2034.

Cholangiocarcinoma Epidemiology

The Cholangiocarcinoma epidemiology section provides insights into the historical and current Cholangiocarcinoma patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Cholangiocarcinoma market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Cholangiocarcinoma Epidemiology @ Cholangiocarcinoma Market Dynamics and Trends

Cholangiocarcinoma Drugs Uptake

This section focuses on the uptake rate of the potential Cholangiocarcinoma drugs recently launched in the Cholangiocarcinoma market or expected to be launched in 2020-2034. The analysis covers the Cholangiocarcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Cholangiocarcinoma Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Cholangiocarcinoma market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Cholangiocarcinoma Therapies and Key Companies

• PEMAZYRE (pemigatinib): Incyte
• TIBSOVO (ivosidenib): Agios Pharmaceuticals/Servier Pharmaceutical
• LYTGOBI (futibatinib): Taiho Pharma
• Imfinzi (durvalumab): Astrazeneca
• Melphalan: Decalth Systems
• Derazantinib: Basilea Pharmaceuticals
• Futibatinib (TAS-120): Taiho Oncology
• E7090: Eisai Pharmaceuticals
• TT-0040: TransThera Sciences (Nanjing), Inc.

Cholangiocarcinoma Pipeline Development Activities

The Cholangiocarcinoma report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Cholangiocarcinoma key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Cholangiocarcinoma pipeline development activities @ Cholangiocarcinoma Clinical Trials and FDA Approvals

Cholangiocarcinoma Therapeutics Assessment

Major key companies are working proactively in the Cholangiocarcinoma Therapeutics market to develop novel therapies which will drive the Cholangiocarcinoma treatment markets in the upcoming years are AstraZeneca (LSE: AZN), Decalth Systems (Private), Power Life Sciences (Private), Genfit (EPA: GNFT), Servier Affaires Médicales (Private), Basilea Pharmaceutica (SWX: BSLN), Taiho Oncology (Private), Eisai Pharmaceuticals (TYO: 4523), TransThera Sciences (Private), Incyte Corporation (NASDAQ: INCY), Roche (SWX: ROG), Agios Pharmaceuticals (NASDAQ: AGIO), Servier Pharmaceuticals (Private), and others.

Cholangiocarcinoma Report Key Insights

1. Cholangiocarcinoma Patient Population

2. Cholangiocarcinoma Market Size and Trends

3. Key Cross Competition in the Cholangiocarcinoma Market

4. Cholangiocarcinoma Market Dynamics (Key Drivers and Barriers)

5. Cholangiocarcinoma Market Opportunities

6. Cholangiocarcinoma Therapeutic Approaches

7. Cholangiocarcinoma Pipeline Analysis

8. Cholangiocarcinoma Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Cholangiocarcinoma Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Cholangiocarcinoma Competitive Intelligence Analysis

4. Cholangiocarcinoma Market Overview at a Glance

5. Cholangiocarcinoma Disease Background and Overview

6. Cholangiocarcinoma Patient Journey

7. Cholangiocarcinoma Epidemiology and Patient Population

8. Cholangiocarcinoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Cholangiocarcinoma Unmet Needs

10. Key Endpoints of Cholangiocarcinoma Treatment

11. Cholangiocarcinoma Marketed Products

12. Cholangiocarcinoma Emerging Therapies

13. Cholangiocarcinoma Seven Major Market Analysis

14. Attribute Analysis

15. Cholangiocarcinoma Market Outlook (7 major markets)

16. Cholangiocarcinoma Access and Reimbursement Overview

17. KOL Views on the Cholangiocarcinoma Market

18. Cholangiocarcinoma Market Drivers

19. Cholangiocarcinoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/ats-conference-coverage

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cholangiocarcinoma Market Forecast 2034: Clinical Trials, Treatment Market, Medication, EMA, PDMA, FDA Approvals, Epidemiology, NICE Approvals, Therapies, Companies by DelveInsight